SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 325 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,920,973 | +24.4% | 15,847 | +17.5% | 0.01% | +14.3% |
| Q2 2023 | $1,544,073 | -9.3% | 13,483 | +9.2% | 0.01% | -12.5% |
| Q1 2023 | $1,702,476 | +9.5% | 12,352 | +3.0% | 0.01% | 0.0% |
| Q4 2022 | $1,554,442 | +27.0% | 11,996 | +8.4% | 0.01% | +14.3% |
| Q3 2022 | $1,224,000 | +51.7% | 11,069 | +2.8% | 0.01% | +40.0% |
| Q2 2022 | $807,000 | -10.5% | 10,764 | -6.8% | 0.01% | +25.0% |
| Q1 2022 | $902,000 | +2.2% | 11,548 | +17.8% | 0.00% | 0.0% |
| Q4 2021 | $883,000 | +31.0% | 9,806 | +34.5% | 0.00% | 0.0% |
| Q3 2021 | $674,000 | +18.9% | 7,292 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $567,000 | -72.3% | 7,292 | -73.4% | 0.00% | -75.0% |
| Q1 2021 | $2,046,000 | -53.1% | 27,451 | +7.2% | 0.01% | -55.6% |
| Q4 2020 | $4,367,000 | +130.4% | 25,613 | +89.8% | 0.03% | +107.7% |
| Q3 2020 | $1,895,000 | +21.8% | 13,495 | +39.1% | 0.01% | 0.0% |
| Q2 2020 | $1,556,000 | +14.2% | 9,702 | -30.3% | 0.01% | 0.0% |
| Q1 2020 | $1,362,000 | -18.8% | 13,924 | +7.1% | 0.01% | 0.0% |
| Q4 2019 | $1,678,000 | +71.2% | 13,007 | 0.0% | 0.01% | +62.5% |
| Q3 2019 | $980,000 | +63.9% | 13,007 | +230.6% | 0.01% | +60.0% |
| Q2 2019 | $598,000 | +27.5% | 3,934 | 0.0% | 0.01% | +25.0% |
| Q1 2019 | $469,000 | +3.3% | 3,934 | -5.3% | 0.00% | -20.0% |
| Q4 2018 | $454,000 | -26.2% | 4,156 | +9.1% | 0.01% | 0.0% |
| Q3 2018 | $615,000 | +22.3% | 3,808 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $503,000 | +97.3% | 3,808 | +10.4% | 0.00% | +100.0% |
| Q1 2018 | $255,000 | +32.8% | 3,448 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $192,000 | +71.4% | 3,448 | +39.5% | 0.00% | +100.0% |
| Q3 2017 | $112,000 | +111.3% | 2,471 | +56.8% | 0.00% | 0.0% |
| Q2 2017 | $53,000 | +39.5% | 1,576 | +22.3% | 0.00% | – |
| Q1 2017 | $38,000 | +8.6% | 1,289 | 0.0% | 0.00% | – |
| Q4 2016 | $35,000 | -55.7% | 1,289 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $79,000 | +295.0% | 1,289 | +21.3% | 0.00% | – |
| Q2 2016 | $20,000 | -4.8% | 1,063 | 0.0% | 0.00% | – |
| Q1 2016 | $21,000 | -48.8% | 1,063 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $41,000 | +192.9% | 1,063 | +141.6% | 0.00% | – |
| Q3 2015 | $14,000 | +100.0% | 440 | +97.3% | 0.00% | – |
| Q2 2015 | $7,000 | – | 223 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |